

American Global Logistics LLC dba AGL (NVO & OFF), 3399 Peachtree Road NE., #1130, Atlanta, GA 30326, *Officers:* Chad J. Rosenberg, President/CEO (Qualifying Individual), Otto J. Valdes, Vice President, *Application Type:* Trade Name Change.

Ark Shipping Line Limited Liability Company (NVO & OFF), 250 Lackland Drive, Suite 6, Middlesex, NJ 08846, *Officer:* Fawwad Mohammad, Chief Executive Manager (Qualifying Individual), *Application Type:* New NVO & OFF License.

Asencoex, LLC (NVO & OFF), 7788 NW 71st Street, Miami, FL 33166, *Officers:* Juan P. Constain, Managing Member (Qualifying Individual), Natalia I. Rondinel, Managing Member, *Application Type:* New NVO & OFF License.

Blue Axis Shipping & Freight Inc (NVO), 1109 Burnett Drive, Allen, TX 75002, *Officer:* Sinu Jacob, President/Secretary/Treasurer (Qualifying Individual), *Application Type:* New NVO License.

Blue Global Line, Inc. dba CFS Logistics (NVO), 455 E. State Parkway, #105, Schaumburg, IL 60173, *Officers:* Kook (A.K.A. Joseph) S. Lee, President/Treasurer/Secretary (Qualifying Individual), Eun J. Lim, Vice President, *Application Type:* New NVO License.

BM Forwarding Inc. (OFF), 1290 Maple View Drive, Pomona, CA 91766, *Officer:* Mei Zhu, President/CEO/Secretary/CFO (Qualifying Individual), *Application Type:* New OFF License.

Brilliant Group Logistics Corp. (NVO), 159 N. Central Avenue, Valley Stream, NY 11580, *Officer:* Shuping Wang, President/VP/Sec/Treasurer (Qualifying Individual), *Application Type:* New NVO License.

Concord Atlantic Inc. dba Concord Atlantic Shipping (NVO & OFF) 10095 Washington Blvd., North, #211 Laurel, MD 20723, *Officer:* Olufemi A. Asabi President, (Qualifying Individual), *Application Type:* New NVO & OFF License.

CTL Lax, Inc. (NVO), 10622 Tammy Street, Cypress, CA 90630, *Officers:* Jason Hsu, Director/Secretary/Treasurer/CFO (Qualifying Individual), Sin F. Chan, Director/President, *Application Type:* New NVO License.

Eagle Van Lines, Inc. (OFF), 5041 Beech Place, Temple Hills, MD 20748, *Officers:* George Georgakopoulos, President (Qualifying Individual), Marika Georgakopoulos, Secretary, *Application Type:* QI Change.

EZ Forwarding LLC (NVO & OFF), 3050 North 29th Court, Hollywood, FL 33020, *Officer:* Frances M. Simons, Vice President (Qualifying Individual), *Application Type:* Trade Name Change.

Fast Global Logistics, LLC (NVO & OFF), 3505 NW 113th Court, Miami, FL 33178, *Officers:* Rayani A. Vllias, Member/Manager/President (Qualifying Individual), Anderson Miera, Member/Manager/Vice President, *Application Type:* New NVO & OFF License.

ISS Marine Services, Inc. dba Inchcape Shipping Services (NVO & OFF), 11 N. Water Street, #9290, Mobile, AL 36602, *Officers:* Elaine T. Dearmond, Vice President (Qualifying Individual), Lar D. Westerberg, CEO, *Application Type:* Add NVO Service.

Jo-Sak Shipping USA, Inc. (NVO & OFF), 3100 Arapahoe Avenue, #104, Boulder, CO 80303, *Officers:* Pauline Yagjhiayan, President (Qualifying Individual), Duncan Alex, Chairman, *Application Type:* Name Change.

Quasar Logistics Inc. (NVO), 18460 Jamaica Avenue, Hollis, NY 11423, *Officers:* Rene G. Madrazo, Chief Logistics Officer (Qualifying Individual), Qaiser Choudri, President, *Application Type:* New NVO License.

Shipping Logistics, LLC (NVO & OFF), 3340-C Greens Road, #200, Houston, TX 77032, *Officer:* Mary K. Francis, Manager (Qualifying Individual), *Application Type:* Add NVO Service.

Tradelanes, Inc. (NVO & OFF), 61 Saint Joseph Street, Suite 1000, Mobile, AL 36602, *Officers:* Raymond K. Jones, Vice President (Qualifying Individual), Lloyd C. Garrison, President, *Application Type:* QI Change.

US Pacific Transportation Group, Inc. (NVO), 1290 Maple View Drive, Pomona, CA 91766, *Officer:* Mei Zhu, President/CEO/Secretary/CFO (Qualifying Individual), *Application Type:* New NVO License.

W8 Shipping LLC (NVO & OFF), 8 Aviation Court, Savannah, GA 31408, *Officers:* Darius Ziulpa, Member (Qualifying Individual), Gediminas Garmus, Member/Manager, *Application Type:* Add NVO Service.

Waterline International Logistics, Inc. (NVO & OFF), 24178 Alicia Parkway, Mission Viejo, CA 92691, *Officer:* Khalid E. Fahssi, Pres/CEO/Treas/CFO/Sec/VP (Qualifying Individual), *Application Type:* New NVO & OFF License.

Dated: May 25, 2012.

**Rachel E. Dickon,**  
*Assistant Secretary.*

[FR Doc. 2012-13216 Filed 5-30-12; 8:45 am]

**BILLING CODE 6730-01-P**

## FEDERAL MARITIME COMMISSION

### Ocean Transportation Intermediary License Revocation

The Federal Maritime Commission hereby gives notice that the following Ocean Transportation Intermediary licenses have been revoked pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. Chapter 409) and the regulations of the Commission pertaining to the licensing of Ocean Transportation Intermediaries, 46 CFR part 515, effective on the corresponding date shown below:

*License Number:* 004661N.

*Name:* Jacob Fleishman

Transportation, Inc.

*Address:* 1177 NW 81st Street, Miami, FL 33150.

*Date Revoked:* April 25, 2012.

*Reason:* Voluntarily surrendered license.

*License Number:* 020163N.

*Name:* Global Services of Nevada, Inc.

*Address:* 1607 Guilford Drive,

Henderson, NV 89014.

*Date Revoked:* May 4, 2012.

*Reason:* Voluntarily surrendered license.

*License Number:* 021803NF.

*Name:* Skyline Customs Services, LLC.

*Address:* 7539 NW 52nd Street,

Miami, FL 33166.

*Date Revoked:* April 30, 2012.

*Reason:* Voluntarily surrendered license.

**Vern W. Hill,**

*Director, Bureau of Certification and Licensing.*

[FR Doc. 2012-13215 Filed 5-30-12; 8:45 am]

**BILLING CODE 6730-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Research Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Juan Ma, Ph.D., Brigham and Women's Hospital and Harvard Medical*

*School*: Based on evidence and findings of an inquiry conducted jointly by Brigham and Women's Hospital (BWH) and Harvard Medical School (HMS) and additional evidence gathered by the Office of Research Integrity (ORI) during its oversight review, ORI found that Dr. Juan Ma, former Research Fellow, BWU, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grant 5 P01 CA120964.

ORI found that the Respondent knowingly and intentionally fabricated and falsified data in portions of figures in an unpublished manuscript titled "TSC1 loss synergizes with KRAS activation in lung cancer development and confers rapamycin sensitivity" by M.-C. Liang, J. Ma, L. Chen, P. Kozlowski, W. Qin, D. Li, T. Shimamura, M.L. Sos, R. Thomas, D. Neil Hayes, M. Meyerson, D.J. Kwiatkowski, and K.-K. Wong, submitted to the *Journal of Clinical Investigation (JCI)* on August 5, 2008, and in revised form on October 21, 2008 (hereafter referred to as the "JCI manuscript"). Specifically, Respondent committed research misconduct by knowingly and intentionally:

- Falsifying and/or fabricating those portions of the immunoblots in JCI manuscript Figure 1C, to show that in Tsc1<sup>L/L</sup> and Tsc1<sup>L/+</sup> mouse lung cancer cells compared with KRAS induced lung cancer cells, there were reduced Tsc1 and Tsc2 protein levels, reduced phospho-AKT-S473 levels, and increased phospho-S6-S249/244 levels, consistent with the hypothesis that introduction of the Tsc1<sup>L</sup> gene resulted in mTORC1 activation.

- Falsifying and/or fabricating those portions of the immunoblots in Figure 3A of the JCI manuscript to show data consistent with the hypothesized TNS null signaling lung tumor cells: Functional loss of Tsc1/Tsc2, high phospho-S6-S249/244 levels, and low phospho-AKT-S473, with recovery of phospho-AKT-S473 after Rapamycin treatment.

- Falsifying and/or fabricating those portions of the immunoblots in Figure 3B of the JCI manuscript by (i) adding a band in the Tsc2 lane for control cells for the IP blot, and (ii) weakening the Tsc2 band for one of the tumor lysates.

- Falsifying and/or fabricating immunoblots in Figures 5A and 5B of the JCI manuscript so that the data appeared to indicate that TSC reconstitution in TSC null (TNS) cell lines led to reduction of pS6-S240/244 levels during serum deprivation (in the absence of growth factors), as well as increased pAKT(S473) levels in response to serum stimulation.

- The JCI manuscript was accepted by JCI on December 8, 2008, but it was withdrawn by one of the authors on January 6, 2009.

ORI found that Respondent's knowing and intentional falsification and fabrication of data constitutes research misconduct within the meaning of 42 CFR 93.103.

The following administrative actions have been implemented for a period of three (3) years, beginning on May 12, 2012:

(1) Any institution that submits an application for U.S. Public Health Service (PHS) support for a research project on which Respondent's participation is proposed or that uses him in any capacity on PHS-supported research must concurrently submit a plan for supervision of his duties to the funding agency for approval; the supervisory plan must be designed to ensure the scientific integrity of his research contribution; Respondent must ensure that a copy of the supervisory plan is also submitted to ORI by the institution; Respondent will not participate in any PHS-supported research until such a supervisory plan is submitted to ORI;

(2) Respondent will ensure that any institution employing him submits, in conjunction with application for PHS funds or any report, manuscript, or abstract of PHS-funded research in which he is involved, a certification that the data provided by him are accurately reported in the application or report; Respondent must ensure that the institution send the certification to ORI; this certification shall be submitted no later than one month before funding and concurrently with any report, manuscript, or abstract; and

(3) Respondent is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

**FOR FURTHER INFORMATION CONTACT:**

Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8800.

**John Dahlberg,**

Director, Division of Investigative Oversight, Office of Research Integrity.

[FR Doc. 2012-13126 Filed 5-30-12; 8:45 am]

**BILLING CODE 4150-31-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH)**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

*Board Public Meeting Times and Dates (All times are Mountain Time):*  
8:15 a.m.–5:15 p.m., June 19, 2012.  
8:15 a.m.–5:45 p.m., June 20, 2012.  
8:15 a.m.–12 p.m., June 21, 2012.

*Public Comment Times and Dates (All times are Mountain Time):*  
5:15 p.m.–6:15 p.m.\*, June 19, 2012.  
6 p.m.–7 p.m.\*, June 20, 2012.

\* Please note that the public comment periods may end before the times indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend public comment sessions at the start times listed.

*Place:* Courtyard Santa Fe, 3347 Cerrillos Road, Santa Fe, New Mexico 87507, Telephone: (800) 777-3347, Fax: (505) 473-5128. Audio Conference Call via FTS Conferencing, the USA toll-free, dial-in number is 1-866-659-0537 with a pass code of 9933701.

*Status:* Open to the public, limited only by the space available. The meeting space accommodates approximately 150 people.

*Background:* The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines which have been promulgated by the Department of Health and Human Services (HHS) as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program, and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC).